Drug Courts pp 127-140 | Cite as

The Pharmacologic Treatment of Alcohol and Drug Addiction

  • Nikita B. Katz
  • Olga A. Katz
  • Steven Mandel


This chapter is about the pharmacologic treatment of drug and alcohol addiction. The National Institute on Drug Abuse has issued a set of principles of drug addiction treatment as a research-based guide for practitioners. These principles are given in Table 8.1 and make it clear that pharmacologic treatment is only one component in a broad range of treatment modalities (1). This chapter reviews the pharmacologic treatments for (1) alcohol; (2) stimulants: cocaine and amphetamines; and (3) opioids and other narcotics.


Opioid Receptor Alcohol Dependence Alcohol Withdrawal Opioid Antagonist Opioid Dependence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    National Institute on Alcoholism and Alcohol Abuse. Ninth Special Report to the U.S. Congress on Alcohol and Health. Rockville, MD: U.S. Department of Health and Human Services; 1997.Google Scholar
  2. 2.
    Armour DJ, Polish JM, Stambul HB. Alcoholism and Treatment. New York: Wiley Publications; 1978.Google Scholar
  3. 3.
    Stine S, Meandzija B, Kosten R. Pharmacologic therapies for opioid addiction. In Graham AW, Schultz TK, eds. Principles of Addiction Medicine, 2nd ed. New York: Society of Addiction Medicine; 1998:545–555.Google Scholar
  4. 4.
    Castaneda R, Cushman P. Alcohol withdrawal: a review of clinical management. J Clin Psychiatry 1989;50(8):278–284.PubMedGoogle Scholar
  5. 5.
    Hall W, Zador D. The alcohol withdrawal syndrome. Lancet 1997;349:1897–1900.PubMedCrossRefGoogle Scholar
  6. 6.
    Holbrook AM, Crowther R, Lotter A. Diagnosis and management of acute alcohol withdrawal. CMAJ 1999;160(5):675–680.PubMedGoogle Scholar
  7. 7.
    Mayo-Smith ME. Pharmacological management of alcohol withdrawal: a metaanalysis and evidence-based practice guideline. JAMA 1997;278(2):144–151.PubMedCrossRefGoogle Scholar
  8. 8.
    Olmedo R, Hoffman RS. Withdrawal syndromes. Emerg Med Clin North Am 2000;18(2):273–288.PubMedCrossRefGoogle Scholar
  9. 9.
    Howard MO. Pharmacological aversion treatment of alcohol dependence: I. Production and prediction of conditioned alcohol aversion. Am J Drug Alcohol Abuse 2001;27:561–585.PubMedCrossRefGoogle Scholar
  10. 10.
    Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 2000;132:26–40.Google Scholar
  11. 11.
    Schurks M, Overlack, Bonnet U. Naltrexone treatment of combined alcohol and opioid dependence: deterioration of co-morbid major depression. Pharmacopsychiatry 2005;38:100–102.PubMedCrossRefGoogle Scholar
  12. 12.
    Myrick H, Anton R. Recent advances in the pharmacotherapy of alcoholism. Curr Psychiatry Rep 2004;6:332–338.PubMedCrossRefGoogle Scholar
  13. 13.
    Scott LJ, Figgitt DP, Keam SJ, Waugh J. Acamprosate: a review of its use in the maintenance of abstinence in patients with alcohol dependence. CNS Drugs 2005;19:445–464.PubMedCrossRefGoogle Scholar
  14. 14.
    Goldstein BI, Diamantouros A, Schaffer A, Naranjo CA. Pharmacotherapy of alcoholism in patients with co-morbid psychiatric disorders. Drugs 2006;66:1229–1237.PubMedCrossRefGoogle Scholar
  15. 15.
    Kongsakon R, Papadopoulos KI, Saguansiritham R. Mirtazapine in amphetamine detoxification: a placebo-controlled pilot study. Int Clin Psychopharmacol 2005;20:253–256.PubMedCrossRefGoogle Scholar
  16. 16.
    Srisurapanont M, Jarusuraisin N, Kittirattanapaiboon P. Treatment for amphetamine dependence and abuse. Cochrane Database Syst Rev 2001;4:CD003022.PubMedGoogle Scholar
  17. 17.
    Grabowski J, Shearer J, Merrill J, Nagus SS. Agonist-like replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav 2004;29:1439–1464.PubMedCrossRefGoogle Scholar
  18. 18.
    Laqueille X, Dervaux A, El Omari F, Kanit M, Bayle FJ. Methylphenidate effective in treating amphetamine abusers with no other psychiatric disorder. Eur Psychiatry 2005;20:456–457.PubMedCrossRefGoogle Scholar
  19. 19.
    Carrera MR, Trigo JM, Wirsching P, Roberts AJ, Janda KD. Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose. Pharmacol Biochem Behav 2005;81:709–714.PubMedCrossRefGoogle Scholar
  20. 20.
    Pan Y. Gao D, Yang W, Cho H, Yang G, Tai HH, Zhan CG. Computational redesign of human butyrylcholinesterase for anticocaine medication. Proc Natl Acad Sci USA 2005;102(46):16656–16661.PubMedCrossRefGoogle Scholar
  21. 21.
    Carrera MR, Kaufmann GF, Mee JM, Meijler MM, Koob GF, Janda KD. Treating cocaine addiction with viruses. Proc Natl Acad Sci USA 2004;101(28):10416–10421.PubMedCrossRefGoogle Scholar
  22. 22.
  23. 23.
  24. 24.
    Bonnet U, Banger M, Leweke EM, Maschke M, Kowalski T, Gastpar M. Treatment of alcohol withdrawal syndrome with gabapentin. Pharmacopsychiatry (Germany) 1999;32(3):107–109.Google Scholar
  25. 25.
    Chatterjee CR, Ringold AL. A case report of reduction in alcohol craving and protection against alcohol withdrawal by gabapentin. J Clin Psychiatry 1999;60:617–620.PubMedGoogle Scholar
  26. 26.
    Li L, Smialek JE. Observations on drug abuse deaths in the state of Maryland. J Forensic Sci 1996;41:106–109.PubMedGoogle Scholar
  27. 27.
    Jaffe JH, Jaffe AB. Opioid-related disorders. In Comprehensive Textbook of Psychiatry, 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2000.Google Scholar
  28. 28.
    Teplin D, Raz B, Daiter J, Varenbut M, Zachos CT, Whang P, Herman S, Chaudry S, Yang M. Measurement of symptom withdrawal severity in a 24-hour period after the anaesthesia-assisted rapid opiate detoxification procedure. Am J Drug Alcohol Abuse 2005;31:327–335.PubMedCrossRefGoogle Scholar
  29. 29.
    Marsch LA, Stephens MA, Mudric T, Strain EC, Bigelow GE, Johnson RE. Predictors of outcome in LAAM, buprenorphine and methadone treatment for opioid dependence. Exp Clin Psychopharmacol 2005;13:293–302.PubMedCrossRefGoogle Scholar
  30. 30.
    Stimmel B, Kreek MJ. Neurobiology of addictive behaviors and its relationship to methadone maintenance. Mt Sinai J Med 2000;67:375–380.PubMedGoogle Scholar
  31. 31.
    Vigezzi P, Guglielmino L, Marzorati P, Silenzio R, DeChiara M, Corrado F, Cocchi L, Cozzolino E. Multimodal drug addiction treatment: a field comparison of methadone and buprenorphine among heroin-and cocaine-dependent patients. J Subst Abuse Treat 2006;31:3–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Newman RG. Expansion of opiate agonist treatment: an historical perspective. Harm Reduct J 2006;3(1):20–45.PubMedCrossRefGoogle Scholar
  33. 33.
    Vocci FJ, Acri J, Elkashef A. Medication development for addictive disorders: the state of the science. Am J Psychiatry 2005;162(8):1432–1440.PubMedCrossRefGoogle Scholar
  34. 34.
    Johnson BA. A synopsis of the pharmacological rationale, properties and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence. Expert Opin Pharmacother 2006;7(8):1065–1073.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Nikita B. Katz
    • 1
  • Olga A. Katz
    • 2
  • Steven Mandel
    • 2
  1. 1.INR/Biomed, Inc.ConcordUSA
  2. 2.Jefferson Medical College, Neurology and Neurophysiology Associates, PCPhiladelphiaUSA

Personalised recommendations